fashion -WSS

fashion

author：hotspot 2025-09-03 12:07:20 - browse：15

Christine Kao/STAT

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

PBMs, the middlemen of drug pricing negotiations, also claim portions of those lucrative rebates for themselves. So when new market developments threaten to diminish or wipe away that revenue stream, PBMs find crafty ways to keep as much of those dollars as possible — often at the expense of employers.

One such case occurred last year, when a wave of Humira biosimilars entered the market and drug companies slashed the list prices of their insulin products. CVS Caremark, the PBM owned by CVS Health that oversees the prescription drug benefits of 103 million people, told its employer clients that it anticipated “more lower-cost products (including specialty biosimilars) may become preferred products” on its lists of approved drugs for 2024, according to documents obtained by STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Readout Newsletter: Amylyx, Aurinia, and IQVIA

focus

WSS

STAT Boddities: What happens to the brain when we get scared?

Too many hospitalized Covid

Why Eli Lilly’s earnings didn’t quite live up to the hype

Juul documents reveal insider tactics on political lobbying

Having children helps parents live longer, especially after age 80

Congress must protect the remaining independent doctors

hotspot

fashion

leisure time

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Congress must protect the remaining independent doctors

United colonoscopy coverage change 'may cost lives,' doctors say

First Opinion Podcast: Long Covid needs a new approach

Hepatitis C has a cure — but many Americans still lack access to it

Too many hospitalized Covid

Hollywood unions extend contract negotiations for actors

Tome Biosciences co

Peter Hotez and the public health issue of online harassment

Senate committee scrutinizes Medicare Advantage brokers

focus

First Opinion Podcast: Long Covid needs a new approach

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Hospital price transparency does save money, advocate argues

Researchers explore possible ties between long Covid, menopause

The EU Joint Clinical Assessment needs to live up to its promise

focus

hotspot

entertainment

focus